IDiyas

For the Inventor, By the Inventor

Somerville, MA, United States of America

Julien Papillon

USPTO Granted Patents = 25 

 

 

Average Co-Inventor Count = 3.8

ph-index = 4

Forward Citations = 45(Granted Patents)


Location History:

  • Cambridge, MA (US) (2013)
  • Somerville, MA (US) (2011 - 2024)

Company Filing History:

goldMedal23 out of 3,923 
 
Novartis Ag
 patents
silverMedal1 out of 30 
 
Bausch + Lomb Ireland Limited
 patents
where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...
Loading Chart...
Loading Chart...
25 patents (USPTO):
1. 12473273 - Quinoline compounds and compositions for inhibiting EZH2 (2025-11-18),
2. 12435040 - 1,3-substituted cyclobutyl derivatives and uses thereof (2025-10-07),
3. 12358906 - Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors (2025-07-15),
4. 11958846 - Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors (2024-04-16),
5. 11845730 - 1,3-substituted cyclobutyl derivatives and uses thereof (2023-12-19),
6. 11505541 - Protein kinase C inhibitors and methods of their use (2022-11-22),
7. 11059804 - Protein kinase C inhibitors and methods of their use (2021-07-13),
8. 10508101 - Protein kinase C inhibitors and methods of their use (2019-12-17),
9. 9845309 - Protein kinase C inhibitors and methods of their use (2017-12-19),
10. 9452998 - Protein kinase C inhibitors and methods of their use (2016-09-27),
11. 9434754 - Use of an adrenal hormone-modifying agent (2016-09-06),
12. 9278969 - Organic compounds (2016-03-08),
13. 9242963 - Organic compounds (2016-01-26),
14. 8835646 - Organic compounds (2014-09-16),
15. 8809545 - Aryl pyridine as aldosterone synthase inhibitors (2014-08-19),

Title: Innovations and Contributions of Julien Papillon

Introduction

Julien Papillon, based in Somerville, MA, is an accomplished inventor with an impressive portfolio of 22 patents. His work primarily focuses on developing compounds and compositions that serve as innovative therapies for various diseases and disorders.

Latest Patents

Among his latest patents, one significant innovation includes "Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors." This patent presents a compound of Formula (I) or a pharmaceutically acceptable salt that has shown promise in treating BRM-mediated and/or BRG1-mediated diseases. Another notable patent is for "1,3-substituted cyclobutyl derivatives and uses thereof," which outlines compounds and pharmaceutical compositions effective in treating conditions mediated by the TRPV1 receptor. This invention also details methods for addressing ocular diseases through therapeutically effective amounts of the compounds described.

Career Highlights

Julien Papillon has made substantial contributions to the field of pharmaceutical research while working at Novartis AG. His expertise and innovative approaches have garnered recognition in the industry, reflecting his commitment to advancing therapeutic options for patients.

Collaborations

Throughout his career, Julien has collaborated with esteemed colleagues such as Qi-Ying Hu and Gary Michael Ksander. These partnerships have fostered the development of groundbreaking innovations and have been integral in amplifying the impact of his research.

Conclusion

Julien Papillon's contributions to patent innovation underscore his dedication to improving healthcare solutions. His extensive experience and notable patents position him as a leading figure in the field, continuing to influence the trajectory of medical therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…